STOCK TITAN

Cns Pharmaceuticals Inc - CNSP STOCK NEWS

Welcome to our dedicated news page for Cns Pharmaceuticals (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on Cns Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cns Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cns Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.56%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
Cns Pharmaceuticals Inc

Nasdaq:CNSP

CNSP Rankings

CNSP Stock Data

2.59M
9.53M
4.42%
3.15%
0.59%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Houston

About CNSP

cns pharmaceuticals, inc., a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. the company's lead drug candidate is berubicin, which completed phase i clinical trial that is used for the treatment of glioblastoma multiforme. it has license agreements with houston pharmaceuticals, inc. and the university of texas m.d. anderson cancer center; and a development agreement with wpd pharmaceuticals inc. cns pharmaceuticals, inc. was founded in 2017 and is based in houston, texas.